MD, PhD, Full Professor in Internal Medicine. Board-certifi ed specialist in Internal Medicine and Endocrinology. Currently part-time position as Professor, Dept of Molecular and Clinical Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.Medical Science Director, Diabetes Disease Area, Cardiovascular/ Gastrointestinal Clinical Development, AstraZeneca R&D. Mölndal, Sweden. During more than 20 years several positions as senior consultant physician, mainly in diabetology and endocrinology at University Hospitals in Göteborg, Lund, Umeå in Sweden. These include senior leadership roles such as Head of Department and Head of Research Units. In the same time period leader of research projects in experimental and clinical diabetology and metabolism. Focus on mechanisms of insulin resistance, in particular translational aspects. Author of approx. 150 scientifi c papers. Since 2007 Medical Science Director in Clinical Development, Diabetes (and Obesity) at AstraZeneca R&D. Leader of a large group of MDs, PhDs and other scientists that is responsible for translational and early clinical research in numerous drug projects. PI or co-PI for several internal and external scientifi c networks and collaborations, for example focusing on mechanisms and markers of insulin resistance and on markers of beta cell function and mass in diabetes.   MD, PhD, Full Professor in Internal Medicine. Board-certifi ed specialist in Internal Medicine and Endocrinology. Currently part-time position as Professor, Dept of Molecular and Clinical Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.Medical Science Director, Diabetes Disease Area, Cardiovascular/ Gastrointestinal Clinical Development, AstraZeneca R&D. Mölndal, Sweden. During more than 20 years several positions as senior consultant physician, mainly in diabetology and endocrinology at University Hospitals in Göteborg, Lund, Umeå in Sweden. These include senior leadership roles such as Head of Department and Head of Research Units. In the same time period leader of research projects in experimental and clinical diabetology and metabolism. Focus on mechanisms of insulin resistance, in particular translational aspects. Author of approx. 150 scientifi c papers. Since 2007 Medical Science Director in Clinical Development, Diabetes (and Obesity) at AstraZeneca R&D. Leader of a large group of MDs, PhDs and other scientists that is responsible for translational and early clinical research in numerous drug projects. PI or co-PI for several internal and external scientifi c networks and collaborations, for example focusing on mechanisms and markers of insulin resistance and on markers of beta cell function and mass in diabetes.  

biomarkers, Molecular biology